FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130406768> ?p ?o ?g. }

• W2130406768 endingPage "1368" @default.
• W2130406768 startingPage "1362" @default.
• W2130406768 abstract "BackgroundWe undertook a randomized phase II trial to test whether the addition of paclitaxel (Taxol) to the cisplatin and ifosfamide (IP) combination could improve objective response (OR) rate, progression-free survival (PFS) and overall survival (OS) in patients with recurrent or metastatic cancer of the uterine cervix.Patients and methodsOne hundred and fifty-three patients were randomly allocated to receive either the IP regimen (ifosfamide 1.5 g/m2, daily, on days 1–3 and cisplatin 70 mg/m2 on day 2) or the same combination with the addition of paclitaxel 175 mg/m2 on day 1 [ifosfamide, paclitaxel and cisplatinum (ITP) regimen]. Cycles were administered every 4 weeks on an outpatient basis.ResultsA modest increase in neurotoxicity was observed with the triplet combination. OR rate was significantly higher in the ITP group (59% versus 33%, P = 0.002). Median PFS was 7.9 and 6.3 months for patients in the ITP and IP arms, respectively (P = 0.023). Median OS was 15.4 months and 13.2 months in the ITP and IP arms, respectively (P = 0.048). In multivariate analysis, the triplet yielded a hazard ratio of 0.70 for relapse or progression (P = 0.046) and 0.75 for death (P = 0.124) compared with the doublet.ConclusionThe ITP combination merits further investigation in randomized phase III studies." @default.
• W2130406768 created "2016-06-24" @default.
• W2130406768 creator A5033573338 @default.
• W2130406768 creator A5036525497 @default.
• W2130406768 creator A5039349296 @default.
• W2130406768 creator A5041575636 @default.
• W2130406768 creator A5044610238 @default.
• W2130406768 creator A5045869380 @default.
• W2130406768 creator A5054990997 @default.
• W2130406768 creator A5060795077 @default.
• W2130406768 date "2009-08-01" @default.
• W2130406768 modified "2023-09-24" @default.
• W2130406768 title "Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study" @default.
• W2130406768 cites W1808173951 @default.
• W2130406768 cites W1840778568 @default.
• W2130406768 cites W1869637333 @default.
• W2130406768 cites W1926137745 @default.
• W2130406768 cites W1932754573 @default.
• W2130406768 cites W2001966180 @default.
• W2130406768 cites W2012800796 @default.
• W2130406768 cites W2023955191 @default.
• W2130406768 cites W2037549607 @default.
• W2130406768 cites W2043103956 @default.
• W2130406768 cites W2053022434 @default.
• W2130406768 cites W2060003714 @default.
• W2130406768 cites W2060113787 @default.
• W2130406768 cites W2061566045 @default.
• W2130406768 cites W2071841151 @default.
• W2130406768 cites W2076264206 @default.
• W2130406768 cites W2087937285 @default.
• W2130406768 cites W2106516999 @default.
• W2130406768 cites W2115408426 @default.
• W2130406768 cites W2126768246 @default.
• W2130406768 cites W2129763891 @default.
• W2130406768 cites W2154000932 @default.
• W2130406768 cites W2154651956 @default.
• W2130406768 cites W2159108273 @default.
• W2130406768 cites W2171725862 @default.
• W2130406768 cites W2235063564 @default.
• W2130406768 cites W2243803571 @default.
• W2130406768 cites W2273450130 @default.
• W2130406768 cites W2318609815 @default.
• W2130406768 doi "https://doi.org/10.1093/annonc/mdn797" @default.
• W2130406768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19457937" @default.
• W2130406768 hasPublicationYear "2009" @default.
• W2130406768 type Work @default.
• W2130406768 sameAs 2130406768 @default.
• W2130406768 citedByCount "25" @default.
• W2130406768 countsByYear W21304067682012 @default.
• W2130406768 countsByYear W21304067682013 @default.
• W2130406768 countsByYear W21304067682014 @default.
• W2130406768 countsByYear W21304067682015 @default.
• W2130406768 countsByYear W21304067682016 @default.
• W2130406768 countsByYear W21304067682017 @default.
• W2130406768 countsByYear W21304067682018 @default.
• W2130406768 countsByYear W21304067682020 @default.
• W2130406768 countsByYear W21304067682022 @default.
• W2130406768 crossrefType "journal-article" @default.
• W2130406768 hasAuthorship W2130406768A5033573338 @default.
• W2130406768 hasAuthorship W2130406768A5036525497 @default.
• W2130406768 hasAuthorship W2130406768A5039349296 @default.
• W2130406768 hasAuthorship W2130406768A5041575636 @default.
• W2130406768 hasAuthorship W2130406768A5044610238 @default.
• W2130406768 hasAuthorship W2130406768A5045869380 @default.
• W2130406768 hasAuthorship W2130406768A5054990997 @default.
• W2130406768 hasAuthorship W2130406768A5060795077 @default.
• W2130406768 hasBestOaLocation W21304067681 @default.
• W2130406768 hasConcept C126322002 @default.
• W2130406768 hasConcept C126894567 @default.
• W2130406768 hasConcept C141071460 @default.
• W2130406768 hasConcept C143998085 @default.
• W2130406768 hasConcept C168563851 @default.
• W2130406768 hasConcept C207103383 @default.
• W2130406768 hasConcept C2776694085 @default.
• W2130406768 hasConcept C2777292972 @default.
• W2130406768 hasConcept C2777506904 @default.
• W2130406768 hasConcept C2778239845 @default.
• W2130406768 hasConcept C2781413609 @default.
• W2130406768 hasConcept C44249647 @default.
• W2130406768 hasConcept C71924100 @default.
• W2130406768 hasConceptScore W2130406768C126322002 @default.
• W2130406768 hasConceptScore W2130406768C126894567 @default.
• W2130406768 hasConceptScore W2130406768C141071460 @default.
• W2130406768 hasConceptScore W2130406768C143998085 @default.
• W2130406768 hasConceptScore W2130406768C168563851 @default.
• W2130406768 hasConceptScore W2130406768C207103383 @default.
• W2130406768 hasConceptScore W2130406768C2776694085 @default.
• W2130406768 hasConceptScore W2130406768C2777292972 @default.
• W2130406768 hasConceptScore W2130406768C2777506904 @default.
• W2130406768 hasConceptScore W2130406768C2778239845 @default.
• W2130406768 hasConceptScore W2130406768C2781413609 @default.
• W2130406768 hasConceptScore W2130406768C44249647 @default.
• W2130406768 hasConceptScore W2130406768C71924100 @default.
• W2130406768 hasIssue "8" @default.
• W2130406768 hasLocation W21304067681 @default.
• W2130406768 hasLocation W21304067682 @default.
• W2130406768 hasOpenAccess W2130406768 @default.
• W2130406768 hasPrimaryLocation W21304067681 @default.

• next